Saturday, October 17, 2026 · Edition updated 6:00 AM ETSAT, OCT 17 · 6 AM ET editionNext edition in Next --:--:--
Get the weekly brief

Testing azelaprag pills with tirzepatide shots for weight in adults 55 and older

Terminated · PHASE 2 · BioAge Labs, Inc.

What this means

This trial was set to compare a pill plus weekly tirzepatide shots with tirzepatide alone for weight. It was stopped early, and no results have been posted, so we cannot tell if it works.

Plain-English summary written by an AI model from the registry listing.

Status
Terminated
Who can join
Ages 55 and over
Where
14 sites, including Arizona, California, Kentucky

Contacts and how to join ↗

The science

Registered title
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
Phase
PHASE 2
Study type
interventional
Conditions
Obesity
What is tested
Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo
Sponsor
BioAge Labs, Inc.
Ages
55 Years to no maximum
Dates
First posted Jul 23, 2024 · updated Mar 13, 2025

Registry summary

This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety.

Estimated Study Length:

  • with the optional prescreening, the study duration may be up to 48 weeks.
  • the treatment duration will be 24 weeks followed by 12 weeks follow-up.
  • the visit frequency will be every 2 weeks for the first 8 weeks of the treatment period and every 4 weeks thereafter.

Sites (14)

  • Site 110, Mesa, Arizona, United States
  • Site 107, Los Angeles, California, United States
  • Site 103, Montclair, California, United States
  • Site 105, Spring Valley, California, United States
  • Site 100, Louisville, Kentucky, United States
  • Site 101, Marrero, Louisiana, United States
  • Site 112, Boston, Massachusetts, United States
  • Site 111, Troy, Michigan, United States
  • Site 113, City of Saint Peters, Missouri, United States
  • Site 106, Butte, Montana, United States
  • Site 109, Fargo, North Dakota, United States
  • Site 108, Beachwood, Ohio, United States
  • Site 102, Dallas, Texas, United States
  • Site 104, St. George, Utah, United States

Related treatments

GLP-1 drugs

More aging trials in these states

Arizona · California · Kentucky · Louisiana · Massachusetts · Michigan · Missouri · Montana · North Dakota · Ohio · Texas · Utah

Report a problem